Evidence map›Paper›PMID 27776524›Full record

Trial reportJournal of translational medicine2016

Pulsed high-dose dexamethasone modulates Th1-/Th2-chemokine imbalance in immune thrombocytopenia.

Zongtang Liu, Meiying Wang, Shufen Zhou, Ji Ma, Yan Shi, Jun Peng, Ming Hou, Chengshan Guo

Abstract readClinical Trial
In one paragraph

Trial report in Journal of translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Imbalance of T Lymphocyte Subsets in Adult Immune Thrombocytopenia.International journal of general medicine · 2021
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zongtang LiuMedical College, Shandong University, Jinan, 250012, China.
Meiying WangDepartment of Rheumatology and Immunology, Peking University Shenzhen Hospital, Shenzhen, 518000, China.
Shufen ZhouDepartment of Rheumatology and Immunology, the Affiliated Shenzhen Baoan Hospital of Southern Medical University, the 2nd Longjing Road, Baoan, Shenzhen, 518101, China.
Ji MaDepartment of Hematology, Qilu Hospital, Shandong University, Jinan, 250012, China.
Yan ShiDepartment of Hematology, Qilu Hospital, Shandong University, Jinan, 250012, China.
Jun PengDepartment of Hematology, Qilu Hospital, Shandong University, Jinan, 250012, China.
Ming HouDepartment of Hematology, Qilu Hospital, Shandong University, Jinan, 250012, China.
Chengshan GuoDepartment of Rheumatology and Immunology, the Affiliated Shenzhen Baoan Hospital of Southern Medical University, the 2nd Longjing Road, Baoan, Shenzhen, 518101, China. guochengshan1@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChemokines and chemokine receptors play important roles in autoimmune diseases; however, their role in immune thrombocytopenia (ITP) is unclear. High-dose dexamethasone (HD-DXM) may become a first-line therapy for adult patients with ITP, but the effect of HD-DXM on chemokines in ITP patients is unknown. Our aim was to investigate the mechanism of pulsed HD-DXM for management of ITP, specifically regarding the chemokine pathways.

methodsTh1-/Th2-associated chemokine and chemokine receptor profiles in ITP patients before and after pulsed HD-DXM was studied. Plasma levels of CCL5 and CXCL11 (Th1-associated) and of CCL11 (Th2-associated) were determined by ELISA. Gene expression of these three chemokines and their corresponding receptors CCR5, CXCR3, and CCR3, in peripheral blood mononuclear cells (PBMCs) was determined by quantitative RT-PCR.

resultsThirty-three of the thirty-eight ITP patients responded effectively to HD-DXM (oral, 40 mg/day, 4 days). In ITP patients, plasma CXCL11 levels increased, while CCL11 and CCL5 decreased compared to controls (P < 0.05). Similarly, gene expression of CXCL11 and its receptor CXCR3 increased, while CCL11 and CCR3 decreased (P < 0.05). CCL5 expression did not significantly change; however, expression of its receptor CCR5 increased (P < 0.05). Interestingly, in the patients who responded to pulsed HD-DXM, CXCL11 and CXCR3 expression was down-regulated, while CCL11 and CCR3 expression was up-regulated (P < 0.05). Meanwhile, CCL5 expression was up-regulated and CCR5 was down-regulated by HD-DXM (P < 0.05).

conclusionsThe abnormal profiles of Th1-/Th2-associated chemokines and chemokine receptors may play important roles in the pathogenesis of ITP. Importantly, regulating Th1 polarization by pulsed HD-DXM may represent a novel approach for immunoregulation in ITP.

Indexed as

AdolescentAdultAgedChemokinesChildDexamethasoneDose-Response Relationship, DrugFemaleHumansMaleMiddle AgedPurpura, Thrombocytopenic, IdiopathicReceptors, ChemokineRNA, MessengerTh1 CellsTh2 CellsChemokinesDexamethasoneReceptors, ChemokineRNA, MessengerChemokineChemokine receptorHigh-dose dexamethasoneImmune thrombocytopeniaTh1 polarization

Identifiers

PMID27776524
PMCPMC5078891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.